Name	: Mrs. GUMMALLA SRAVAN	гні		
PID No.	: MED111017297	Register On : 1	2/03/2022 9:39 AM	M
SID No.	: 222005308	Collection On : 1	2/03/2022 10:40 AM	
Age / Sex	: 26 Year(s) / Female	Report On :	12/03/2022 9:10 PM	MEDALL
Туре	: OP	Printed On : 1	4/03/2022 10:02 AM	
Ref. Dr	: MediWheel			
Investigation		<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
TYPINC		'O' 'Positive'		
	ood/Agglutination) RETATION: Reconfirm the Blood g	roup and Typing befor	a blood transfusion	
	e Blood Count With - ESR	Toup and Typing before		
Haemog (EDTA Bl	lobin ood/Spectrophotometry)	12.4	g/dL	12.5 - 16.0
	Cell Volume(PCV)/Haematocrit ood/Derived from Impedance)	36.0	%	37 - 47
RBC Co (EDTA Bl	unt ood/Impedance Variation)	4.27	mill/cu.mm	4.2 - 5.4
	orpuscular Volume(MCV) ood/Derived from Impedance)	84.4	fL	78 - 100
	orpuscular Haemoglobin(MCH) ood/Derived from Impedance)	28.9	pg	27 - 32
concentr	orpuscular Haemoglobin ation(MCHC) ood/Derived from Impedance)	34.3	g/dL	32 - 36
RDW-C		12.9	%	11.5 - 16.0
RDW-SI		38.5	fL	39 - 46
	ukocyte Count (TC) ood/Impedance Variation)	9500	cells/cu.mm	4000 - 11000
Neutropl (EDTA Bl <i>Cytometry</i>	ood/Impedance Variation & Flow	70.8	%	40 - 75
Lympho (EDTA Bl <i>Cytometry</i>)	ood/Impedance Variation & Flow	21.3	%	20 - 45
Eosinopl (EDTA Bl Cytometry)	ood/Impedance Variation & Flow	1.0	%	01 - 06



VERIFIED BY



APPROVED BY

The results pertain to sample tested.

Page 1 of 7

Name	: Mrs. GUMMALLA SRAVAN	тні		
PID No.	: MED111017297	Register On	: 12/03/2022 9:39 AM	\mathbf{C}
SID No.	: 222005308	Collection On	: 12/03/2022 10:40 AM	
Age / Sex	: 26 Year(s) / Female	Report On	: 12/03/2022 9:10 PM	MEDALL
Туре	: OP	Printed On	: 14/03/2022 10:02 AM	
Ref. Dr	: MediWheel			

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	6.2	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.7	%	00 - 02
INTERPRETATION: Tests done on Automated	l Five Part cell coun	ter. All abnormal results a	are reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	6.7	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.0	10^3 / µl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.1	10^3 / µl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.6	10^3 / µl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.1	10^3 / µl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	247	10^3 / µl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	9.7	fL	8.0 - 13.3
PCT (EDTA Blood'Automated Blood cell Counter)	0.240	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	5	mm/hr	< 20
BUN / Creatinine Ratio	10.9		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	89.1	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125

ID(PATH) O R ULTANT - PATHOLOGIST REG NO:116685 NSUL VERIFIED BY

Consultant Pathologist Reg No : 73347 Dr.

Diabetic: >= 126

APPROVED BY

The results pertain to sample tested.

Page 2 of 7

Name	: Mrs. GUMMALLA SRAVAN	ГНІ				
PID No.	: MED111017297	Register On : 12	/03/2022 9:39 AM	M		
SID No.	: 222005308	Collection On : 12	2/03/2022 10:40 AM			
Age / Sex	: 26 Year(s) / Female	Report On : 12	2/03/2022 9:10 PM	MEDALL		
Туре	: OP	Printed On : 14	I/03/2022 10:02 AM			
Ref. Dr	: MediWheel					
Investiga	Investigation Observed Unit Biological Value Reference Interval					
INTERPE blood gluc		uantity and time of food	intake, Physical activity, l	Psychological stress, and drugs can influence		
	Fasting (Urine) GOD - POD)	Negative		Negative		
	Postprandial (PPBS) PP/GOD-PAP)	110.1	mg/dL	70 - 140		
Factors su Fasting blo		Postprandial glucose, b	ecause of physiological su	d drugs can influence blood glucose level. Irge in Postprandial Insulin secretion, Insulin tion during treatment for Diabetes.		
Urine Gl (Urine - PF	ucose(PP-2 hours)	Negative		Negative		
	rea Nitrogen (BUN) ease UV/derived)	7.0	mg/dL	7.0 - 21		
Creatinin (Serum/Ma	ne odified Jaffe)	0.64	mg/dL	0.6 - 1.1		
ingestion of	of cooked meat, consuming Protein/	Creatine supplements, D	iabetic Ketoacidosis, prole	vere dehydration, Pre-eclampsia, increased onged fasting, renal dysfunction and drugs , chemotherapeutic agent such as flucytosine		
Uric Aci (Serum/En		2.3	mg/dL	2.6 - 6.0		
<u>Liver Fu</u>	nction Test					
Bilirubin (Serum/DC	(Total) CA with ATCS)	0.35	mg/dL	0.1 - 1.2		
Bilirubin (Serum/Dia	(Direct) azotized Sulfanilic Acid)	0.13	mg/dL	0.0 - 0.3		
Bilirubin (Serum/De	(Indirect) rived)	0.22	mg/dL	0.1 - 1.0		
Aminotra	ST (Aspartate ansferase) odified IFCC)	24.1	U/L	5 - 40		
	LT (Alanine Aminotransferase) <i>adified IFCC</i>)	14.4	U/L	5 - 41		



Saravanan M.D(Path) Isultant Pathologist Reg No : 73347 Con

APPROVED BY

The results pertain to sample tested.

Page 3 of 7

Name	: Mrs. GUMMALLA SRAVAN	ГНІ		
PID No.	: MED111017297	Register On	: 12/03/2022 9:39 AM	
SID No.	: 222005308	Collection On	: 12/03/2022 10:40 AM	
Age / Sex	: 26 Year(s) / Female	Report On	: 12/03/2022 9:10 PM	N
Туре	: OP	Printed On	: 14/03/2022 10:02 AM	
Ref. Dr	: MediWheel			

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	10.6	U/L	< 38
Alkaline Phosphatase (SAP) (Serum/ <i>Modified IFCC</i>)	53.8	U/L	42 - 98
Total Protein (Serum/Biuret)	6.86	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.10	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.76	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	1.49		1.1 - 2.2
Lipid Profile			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	117.7	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	63.8	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the "usual" circulating level of triglycerides during most part of the day.

HDL Cholesterol	
(Serum/Immunoinhibition)	

40.2

mg/dL

Optimal(Negative Risk Factor): >= 60 Borderline: 50 - 59 High Risk: < 50

TH) CONSULT HOLOGIST **REG NO:116685** VERIFIED BY

D(Path) sultant Pathologist Reg No : 73347 CO

APPROVED BY

The results pertain to sample tested.

Page 4 of 7

Name	: Mrs. GUMMALLA SRAVAN	тні	
PID No.	: MED111017297	Register On : 12/03/2022 9:39 AM	\mathbf{C}
SID No.	: 222005308	Collection On : 12/03/2022 10:40 AM	
Age / Sex	: 26 Year(s) / Female	Report On : 12/03/2022 9:10 PM	MEDALL
Туре	: OP	Printed On : 14/03/2022 10:02 AM	
Ref. Dr	: MediWheel		

Investigation **Observed** <u>Unit</u> **Biological Value Reference Interval** Optimal: < 100 LDL Cholesterol 64.7 mg/dL Above Optimal: 100 - 129 (Serum/Calculated) Borderline: 130 - 159 High: 160 - 189 Very High: >= 190 12.8 mg/dL < 30 VLDL Cholesterol (Serum/Calculated) 77.5 mg/dL Optimal: < 130 Non HDL Cholesterol Above Optimal: 130 - 159 (Serum/Calculated) Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

INTERPRETATION: 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio (Serum/ <i>Calculated</i>)	2.9		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/ <i>Calculated</i>)	1.6		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	1.6		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
<u>Glycosylated Haemoglobin (HbA1c)</u>			
НЬА1С	4.8	%	Normal: 4.5 - 5.6

INTERPRETATION: If Diabetes - Good control : 6.1 - 7.0 %, Fair control : 7.1 - 8.0 %, Poor control >= 8.1 %

REG NO:116685 VERIFIED BY

(Whole Blood/HPLC)

(Path) ant Pathologist

Prediabetes: 5.7 - 6.4

Diabetic: >= 6.5

APPROVED BY

The results pertain to sample tested.

Page 5 of 7

Name	: Mrs. GUMMALLA SRAVAN	ТНІ			
PID No.	: MED111017297	Register On :	12/03/2022 9:39 AM	M	
SID No.	: 222005308	Collection On :	12/03/2022 10:40 AM		
Age / Sex	: 26 Year(s) / Female	Report On :	12/03/2022 9:10 PM	MEDALL	
Туре	: OP	Printed On :	14/03/2022 10:02 AM		
Ref. Dr	: MediWheel				
Investiga	ation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval	
Estimate (Whole Blo	d Average Glucose	91.06	mg/dL		
HbA1c pro control as Conditions hypertrigh Conditions ingestion,	compared to blood and urinary gluco s that prolong RBC life span like Iro yceridemia,hyperbilirubinemia,Drug	ose determinations. n deficiency anemia, V s, Alcohol, Lead Poisc te or chronic blood los	- Vitamin B12 & Folate defi- oning, Asplenia can give fa s, hemolytic anemia, Hem		
(Serum/Ch	odothyronine) - Total emiluminescent Immunometric Assay	1.11	ng/ml	0.7 - 2.04	
(CLIA)) INTERPRETATION: Comment : Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.					
	emiluminescent Immunometric Assay	9.56	µg/dl	4.2 - 12.0	
Comment Total T4 v	-	on like pregnancy, dru	gs, nephrosis etc. In such o	cases, Free T4 is recommended as it is	
	yroid Stimulating Hormone) emiluminescent Immunometric Assay	0.99	µIU/mL	0.35 - 5.50	
Reference 1 st trimes 2 nd trimes (Indian Th Comment 1.TSH refe 2.TSH Lev be of the o	erence range during pregnancy depen	n, reaching peak levels as influence on the me	between 2-4am and at a measured serum TSH concer		
	/			B	



ant Pathologist No : 73347 Reg

APPROVED BY

The results pertain to sample tested.

Page 6 of 7

Name	: Mrs. GUMMALLA SRAVANT	HI		
PID No.	: MED111017297	Register On	: 12/03/2022 9:39 AM	•
SID No.	: 222005308	Collection On	: 12/03/2022 10:40 AM	
Age / Sex	: 26 Year(s) / Female	Report On	: 12/03/2022 9:10 PM	MEI
Туре	: OP	Printed On	: 14/03/2022 10:02 AM	

MEDALL

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
<u>Urine Analysis - Routine</u>			
COLOUR (Urine)	Pale Yellow		Yellow to Amber
APPEARANCE (Urine)	Clear		Clear
Protein (Urine/Protein error of indicator)	Negative		Negative
Glucose (Urine/GOD - POD)	Negative		Negative
Pus Cells (Urine/Automated – Flow cytometry)	1 - 2	/hpf	NIL
Epithelial Cells (Urine/Automated – Flow cytometry)	1 - 2	/hpf	NIL
RBCs (Urine/Automated – Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Automated – Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Automated – Flow cytometry)	NIL	/hpf	NIL
Others (Urine)	NIL		

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.

IOAH D(PATH) NSUL IOLOGIST AT N **REG NO:116685** VERIFIED BY

Ref. Dr

: MediWheel



APPROVED BY

-- End of Report --

The results pertain to sample tested.